Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 18.00
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.778%)
Open: 18.25
High: 18.25
Low: 18.25
Prev. Close: 18.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Arix backs buyback; 88 Energy notes share price surge

Mon, 15th Mar 2021 21:44

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Arix Bioscience PLC - focused on investing in biotech companies - Says board approves buyback of up to GBP25 million worth of shares. "The share buyback programme is consistent with Arix's strategy of creating and delivering value for all stakeholders and follows shareholder consultation as part of the company's stated commitment to keep use of cash under review, following the trade sale of VelosBio," Arix says.

----------

88 Energy Ltd - Alaska-focused oil producer - Says not aware of any reason for recent share price increase. Shares closed 84% higher on Monday.

----------

Rainbow Rare Earths Ltd - Burundi, East Africa-focused rare earth element miner - Calls on ANSTO Minerals to advance flow sheet process work at Phalaborwa rare earths project, South Africa. "ANSTO has world-leading expertise in the processing of critical and strategic minerals, including rare earths. With over 40 years' experience in providing practical solutions and innovative technology to industry," Rainbow says.

----------

Power Metal Resources PLC - metal exploration and development company - To make final earn-in payment of CAD200,000, about GBP114,349, to secure 30% stake in Silver Peak silver project, Canada. Will issue 5.1 million shares. Says new company being formed to hold 100% stake in project, though Power Metal will retain 30% interest. Also updates on drilling at Molopo Farms Complex in Botswana by Kalahari Key Mineral Exploration Pty Ltd. Says third drill hole of 2,505 metre programme begins. Power Metal holds 18% stake in Kalahari Key.

----------

Atalaya Mining PLC - Cyprus-based copper producer - Makes deferred payment of EUR53 million to Astor Management AG in relation to arrangements the duo entered into for Proyecto Riotinto in 2008. Atalaya adds: "The Court of Appeal supported the view of the High Court in determining that the deferred consideration to be paid by the company had not yet fallen due but would only be payable out of excess cash. Despite the company believing that it has not yet generated excess cash to incur an immediate payment, the board believes that now is the appropriate time to pay the deferred consideration and remove the timing uncertainty from the balance sheet."

----------

Zephyr Energy PLC - oil and gas company focused on the US upstream oil and gas sector - Reports on analysis of Paradox Basin, Utah. Says initial findings show "evidence of hydrocarbon saturation across" Cane Creek reservoir at project. "Zephyr's board has therefore elected to proceed with the near-term drilling of a side track lateral off the State 16-2 well," Zephyr adds.

----------

Independent Oil & Gas PLC - UK gas company targeting high returns - Says "subsurface understanding" of Goddard, or P2438, and Abbeydale Area, P2442, licenses in UK southern North Sea improved by seismic data. "This enhances the potential to create two new incremental high-return gas hubs, a northern hub in P2438 and a southern hub in P2442, in line with company strategy," Independent adds. Says 2C contingent resources at Goddard upped to 132 billion cubic feet of gas from 108 bcf.

----------

Eco Atlantic Oil & Gas Ltd - oil and gas exploration company focused on Guyana and Namibia - Says joint-venture partners at Orinduik Block, offshore Guyana enter into first renewal period of Orinduik petroleum prospecting license. "The first renewal period sees the JV partners maintain control of the licence through to January 13, 2023 and until the second renewal period," Eco Atlantic says. Says Guyana's Department of Energy approve transfer of the Total E&P Guyana BV's 25% working interest in project to TOQAP Guyana BV. Total E&P Guyana has 60% stake in new company, while Qatar Petroleum has 40% interest. TOQAP Guyana has 25% stake in Orinduik, operator Tullow Guyana BV holds 60%, while Eco Atlantic holds 15%.

----------

Altus Strategies PLC - Africa-focused mining royalty company - Granted three copper and silver exploration projects in Morocco. "The projects were awarded to the company's 100% owned subsidiary, Aterian Resources Ltd, following a competitive tender process," Altus says.

----------

Ariana Resources PLC - exploration and development company operating in Europe - Says 2021 gold output from 24%-owned Kiziltepe asset to be around 19,000 ounces of gold, "90% above feasibility plan for this approximate stage of mine life".

----------

Eurasia Mining PLC - palladium, platinum, rhodium, iridium and gold producing company - Says technical project for West Kytlim project submitted to Russian regulators. Adds that final approval for West Kytlim Flanks, areas surrounding the project, is "expected soon".

----------

Scirocco Energy PLC - AIM-listed investment firm seeking production and development opportunities within the European energy market - Fully impairs value of holding in Ausable Reef gas assets and incurs only "nominal" hit in 2020.

----------

CEPS PLC - Bath, England-based investment company focussed on the industrial sector - Hickton Group Ltd, its 55%-owned subsidiary, completes buy of Millington Lord Ltd from GT Realisations Ltd for up to GBP1.1 million. Consideration includes upfront GBP700,000, further GBP299,999 deferred in two instalments and possible GBP100,000 in performance-based targets.

----------

Utilico Emerging Markets Trust PLC - invests in infrastructure and utility and related sectors in emerging markets - Extends USD50 million multicurrency revolving facility to March 15, 2024.

----------

Pires Investments PLC - invests in companies that have the potential for major transformation and exponential growth - Invests GBP250,000 in Polience Ltd, a provider of data intelligence used to fight crime and terrorism. Says Sure Valley Ventures, in which Pires has a 20% stake, invested GBP750,000.

----------

Alternative Credit Investments PLC - investor in credit assets and formerly known as Pollen Street Secured Lending PLC - Says GBP639.2 million takeover by US-based Waterfall Asset Management becomes effective. Shares were suspended on Monday.

----------

Yellow Cake PLC - Jersey-based uranium investor - Informs NAC Kazatomprom JSC it plans to exercise full USD100 million uranium purchase option under agreement. Expects delivery or triuranium octoxide between April and August. Also agrees to purchase further 440,000 pounds of triuranium octoxide for USD12 million.

----------

FastForward Innovations Ltd - investor in life sciences and technology businesses particularly within the medical cannabis field - Says investee Fralis LLC, or Leap Gaming, extends partnership with Kaizen Gaming for rollout of EuroLeague Instant Legends on Kaizen's platforms. FastForward adds: "As announced on February 2, 2021, EuroLeague Instant Legends is a unique new betting product created by Leap Gaming and launched by IMG Arena in partnership with EuroLeague Basketball."

----------

Schroder UK Public Private Trust PLC - formerly Woodford Patient Capital Trust, invests in both listed and private UK companies - Completes sale of seven assets to Rosetta Capital VI LP. "The company received initial proceeds of approximately GBP52.9 million, out of which GBP1.0 million results from a positive adjustment to the acquisition price due to changes in the values of the listed portfolio companies Mereo BioPharma and ReNeuron on an aggregated basis," Schroder says. May also receive GBP5.0 million in contingent payments.

----------

RTW Venture Fund Ltd - investment company focused on the life sciences sector - Says portfolio company Prometheus Biosciences Inc raises USD190 million in "significantly upsized" initial public offering at USD19.00 per share. "On the first day of trading, Prometheus' share price increased by 33% to close at USD25.29 per share," RTW adds.

----------

Blackrock Smaller Companies Trust PLC - investment trust focused on smaller UK quoted companies - Mulling removing requirement that value of AIM-listed holdings must not exceed 50% of portfolio. Says some AIM holdings have "performed well" and company would rather not "be required to dispose of these AIM stocks solely as a result of circumstances where the performance of these stocks has brought the Company’s total AIM holdings close to the current 50% limit".

----------

Paragon Banking Group PLC - Solihull, West Midlands-based mortgage, savings and business finance provider - Launches tender offer to repurchase GBP150.0 million fixed rate reset callable subordinated tier 2 notes due 2026

----------

Henry Boot PLC - Sheffield-based construction and property development - Begins work on a major GBP42.5 million urban development scheme in the city centre of Sheffield. Henry Boot Construction selected on two developments within the Heart of the City scheme, to build a new low-carbon office building, covering 70,000 square foot over 7 floors, a food hall and live entertainment venue.

----------

Ince Group PLC - London-based legal and professional services company - Launches a "know-your-customer" solution alongside technology providers eLegal, Yoti and Arachnys in a bid to stem money laundering. Solution will be geared towards customers in real estate sector. "The launch of the new digital KYC solution comes at a time when the real estate sector is facing significant regulatory pressure to strengthen its approach to money laundering. With over GBP4 billion of property in London estimated to be owned by individuals or companies with a high money laundering risk," Ince says.

----------

Destiny Pharma PLC - clinical stage biotechnology company based in Brighton, England - Teams with US government's National Institute of Allergy & Infectious Diseases to probe Destiny's XF-73 as means of preventing infection in open wounds and broken skin. "Destiny Pharma will utilize NIAID's preclinical services programme to complete the preclinical safety studies that will support the planned clinical development in serious wound infections. Destiny Pharma will provide the XF-73 formulation to be tested in these preclinical studies and the project is planned to complete in 2022," Destiny adds.

----------

Omega Diagnostics Group PLC - sells wide range of specialist products, primarily in the immunoassay, in-vitro diagnostics market - Cautions that a contract with the UK government stated to be worth GBP374 million is just its maximum value, so should not be used "as an estimate or forecast of the actual likely value of purchase orders". "The value of future purchase orders may be substantially less than stated in yesterday's public government disclosure," Omega says. Later adds that it was one of two companies picked to supply UK government with rapid lateral flow tests for Covid-19.

----------

Renalytix AI PLC - Cardiff, Wales-based clinical diagnostics company - Says the Centers for Medicare & Medicaid Services in US will delay implementation of new Medicare Coverage of Innovative Technology rules by 60 days, to allow for 30 days of additional public feedback. "RenalytixAI expects the MCIT rule, as is or amended, will become effective within the expected 2021 FDA [US Food & Drug Administration] review and clearance period for KidneyIntelX and will have no material effect on the RenalytixAI business plan," company says.

----------

Actual Experience PLC - AIM-listed analytics-as-a-service company - Gets new Human Experience Management, or HXM, order from channel partner. "This purchase order evidences further endorsement from our channel partner in deploying our technology to its global blue chip customer base," Actual Experience Chief Executive Officer Dave Page says.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
22 Dec 2022 11:25

Destiny Pharma on track for commercial agreement for NTCD-M3 drug

(Alliance News) - Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.

Read more
7 Dec 2022 17:35

Destiny Pharma eyes potential billion dollar returns from Nasal asset

(Alliance News) - Destiny Pharma PLC on Wednesday said it has finalised development plans for phase three testing of its late-stage clinical asset, XF-73 Nasal, which aims to prevent post-surgical staphylococcal infections.

Read more
7 Dec 2022 16:27

Destiny Pharma finalises plans for next study of its lead asset

(Sharecast News) - Biotechnology company Destiny Pharma has finalised plans for phase-three studies of its late-stage clinical asset 'XF-73 Nasal', it announced on Wednesday.

Read more
15 Nov 2022 16:16

Destiny Pharma starts new drug study for its skin infection treatment

(Alliance News) - Destiny Pharma PLC on Tuesday said it had started a safety study to enable its XF-73 treatment to be labelled as an Investigational New Drug.

Read more
15 Nov 2022 12:53

Destiny Pharma starts new safety study of dermal formulation

(Sharecast News) - Biotechnology developer Destiny Pharma announced the start of an investigational new drug (IND)-enabling safety study with its novel 'XF-73 Dermal' formulation.

Read more
8 Sep 2022 15:17

Destiny Pharma loss widens, pins hope on late stage clinical assets

(Alliance News) - Destiny Pharma PLC on Thursday reported a widened interim loss, as it progresses two key clinical assets.

Read more
7 Sep 2022 17:21

Destiny Pharma gets positive EMA feedback for gut bacteria treatment

(Alliance News) - Destiny Pharma PLC on Wednesday announced that it had received positive feedback from the European Medicine Agency on its NTCD-M3 phase 3 development plans.

Read more
7 Sep 2022 08:06

Destiny Pharma receives 'positive feedback' from EMA on NTCD-M3

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma has received "positive feedback" from the European Medicine Agency regarding the proposed Phase III development programme of its new antibiotic treatment.

Read more
1 Sep 2022 15:59

UK earnings, trading statements calendar - next 7 days

Friday 2 September 
Ashmore Group PLCFull Year Results
Monday 5 September 
Belvoir Group PLCHalf Year Results
Dechra Pharmaceuticals PLCFull Year Results
Tuesday 6 September 
Accrol Group Holdings PLCFull Year Results
Alumasc Group PLCFull Year Results
Ashtead Group PLCQ1 Results
Capricorn Energy PLCHalf Year Results
Gamma Communications PLCHalf Year Results
Headlam Group PLCHalf Year Results
Inspired PLCHalf Year Results
IQE PLCHalf Year Results
Lords Group Trading PLCHalf Year Results
Luceco PLCHalf Year Results
Michelmersh Brick Holdings PLCHalf Year Results
Midwich Group PLCHalf Year Results
NCC Group PLCFull Year Results
PCI-PAL PLCFull Year Results
Pebble Group PLCHalf Year Results
Quixant PLCHalf Year Results
STV Group PLCHalf Year Results
WAG Payment Solutions PLCHalf Year Results
WANdisco PLCHalf Year Results
Wednesday 7 September 
Bakkavor Group PLCHalf Year Results
Barratt Developments PLCFull Year Results
Equals Group PLCHalf Year Results
M Winkworth PLCHalf Year Results
Malin Corp PLCHalf Year Results
Petropavlovsk PLCHalf Year Results
Somero Enterprises IncHalf Year Results
Tissue Regenix Group PLCHalf Year Results
WH Smith PLCTrading Statement
Thursday 8 September 
Arecor Therapeutics PLCHalf Year Results
Cairn Homes PLCHalf Year Results
Curtis Banks Group PLCHalf Year Results
Darktrace PLCFull Year Results
Destiny Pharma PLCHalf Year Results
Duke Royalty LtdFull Year Results
Emis Group PLCHalf Year Results
Energean PLCHalf Year Results
Funding Circle Holdings PLCHalf Year Results
Genus PLCFull Year Results
International Public Partnerships LtdHalf Year Results
Melrose Industries PLCHalf Year Results
Mpac Group PLCHalf Year Results
Oakley Capital Investments LtdHalf Year Results
Open Orphan PLCHalf Year Results
Restaurant Group PLCHalf Year Results
Safestore Holdings PLCQ3 Results
Severfield PLCFull Year Results
Shield Therapeutics PLCHalf Year Results
SourceBio International PLCHalf Year Results
Spire Healthcare Group PLCHalf Year Results
Sylvania Platinum LtdFull Year Results
Vistry Group PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
26 Jul 2022 22:16

TRADING UPDATES: De La Rue cancels contract; Apollon buys in Jamaica

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
19 Jul 2022 20:01

TRADING UPDATES: Capital backs outlook; Northcoders trades well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
12 Jul 2022 15:39

Destiny Pharma awarded Cystic Fibrosis Foundation project

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation, it announced on Tuesday.

Read more
12 Jul 2022 12:07

IN BRIEF: Destiny Pharma receives undisclosed grant for MRSA study

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Receives undisclosed grant from Maryland-based non profit Cystic Fibrosis Foundation for a study on its drug candidate XF-73 on disease-causing bacteria MRSA.

Read more
7 Jul 2022 20:38

IN BRIEF: Destiny Pharma XF-73 shown to enhance activity of two drugs

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - New data on its XF-73 drug show that it can boost the effectiveness of current standard of care antibiotics when used in combinational therapy. The new in-vitro data stemmed from experiments by studies at the School of Dentistry, Cardiff University, for the potential for XF-based drugs to enhance the effectiveness of key antibacterial treatments. When combined with polymyxin B, a last resort antibacterial drug used to treat life-threatening lung bacterial infections, XF-73 enhanced polymyxin B potency against Pseudomonas aeruginosa, a top priority WHO bacterial pathogen, by 4-fold, the research found.

Read more
5 Jul 2022 11:43

IN BRIEF: Destiny Pharma begins research on XF-73 for oral mucositis

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Starts new research programme in the US on oral mucositis, an inflammation of the mouth that is a common side effect of chemotherapy and radiotherapy. Firm tests its experimental drug candidate XF-73 as potential preventive medicine to ease suffering from oral mucositis. Explains that XF-73 has shown unique antimicrobial properties in phase 2 clinical trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.